Oral Anticoagulants Reduce Stroke Risk in Intermediate-Risk Atrial Fibrillation Patients

The SINGLE-AF clinical trial demonstrates that oral anticoagulant therapy significantly reduces adverse clinical events in patients with atrial fibrillation at intermediate stroke risk compared to those receiving no anticoagulation. The findings, presented at ESC Congress 2026 and published in the New England Journal of Medicine, suggest that anticoagulation therapy should be considered for this previously uncertain patient population. Atrial fibrillation affects millions globally and increases stroke risk substantially. These results provide evidence-based guidance for physicians treating intermediate-risk patients, potentially preventing thousands of strokes and improving patient outcomes in Puerto Rico and worldwide.